These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 23675001)
1. An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice. Takasu T; Kakuta H; Sasamata M; Yamagishi S Int J Biomed Sci; 2006 Dec; 2(4):333-6. PubMed ID: 23675001 [TBL] [Abstract][Full Text] [Related]
2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S; Takeuchi M Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852 [TBL] [Abstract][Full Text] [Related]
3. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Yamagishi S; Takenaka K; Inoue H Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710 [TBL] [Abstract][Full Text] [Related]
4. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Yamagishi S; Nakamura K; Matsui T Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961 [TBL] [Abstract][Full Text] [Related]
5. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328 [TBL] [Abstract][Full Text] [Related]
6. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. Suksomboon N; Poolsup N; Prasit T J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583 [TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480 [TBL] [Abstract][Full Text] [Related]
8. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. Iwai M; Kanno H; Tomono Y; Inaba S; Senba I; Furuno M; Mogi M; Horiuchi M J Hypertens; 2010 Jul; 28(7):1471-81. PubMed ID: 20543712 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Rong X; Li Y; Ebihara K; Zhao M; Naowaboot J; Kusakabe T; Kuwahara K; Murray M; Nakao K Diabetologia; 2010 Aug; 53(8):1727-31. PubMed ID: 20390403 [TBL] [Abstract][Full Text] [Related]
11. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620 [TBL] [Abstract][Full Text] [Related]
12. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391 [TBL] [Abstract][Full Text] [Related]
13. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats. Younis F; Oron Y; Limor R; Stern N; Rosenthal T Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685 [TBL] [Abstract][Full Text] [Related]
14. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses. Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487 [TBL] [Abstract][Full Text] [Related]
15. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes. Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293 [TBL] [Abstract][Full Text] [Related]
16. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723 [TBL] [Abstract][Full Text] [Related]
17. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150 [TBL] [Abstract][Full Text] [Related]
18. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice. Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369 [TBL] [Abstract][Full Text] [Related]